Pfizer's Oncology Strategy Centers On Three Anchors To Steady The Ship
Executive Summary
Ibrance, Xtandi and Bavencio are positioned as three anchor drugs with big market potential and opportunities for expansion, President-Worldwide R&D Mikael Dolsten said at a recent briefing at Pfizer's headquarters.